$HWBK

Hawthorn Bancshares, Inc. Reports 25.9% Increase in First Quarter 2026 Net Income to $6.8 Million

Hawthorn Bancshares, Inc. announced a significant increase in its first quarter 2026 net income, reaching $6.8 million, a 25.9% rise compared to the previous year. The company also reported an improved efficiency ratio of 60.46% and a robust net interest margin of 4.07%. Despite slight decreases in loans and deposits, Hawthorn Bancshares maintained a "well capitalized" status and approved a quarterly cash dividend of $0.21 per share.

Original reporting
Published Apr 29, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hawthorn Bancshares, Inc. Reports 25.9% Increase in First Quarter 2026 Net Income to $6.8 Million — source image
Decision brief

The 30-second read

$HWBKBullishMed
01

Why it matters

The earnings boost may lead to increased investor confidence and stock appreciation.

02

Market read

Significant for regional banking investors; limited global impact.

03

What to watch

Potential interest rate changes or regulatory adjustments could impact future earnings.

Relevance 6/10Timing: Immediate, given recent earnings release and market reaction.

Background

Hawthorn Bancshares' Q1 2026 earnings demonstrate resilience amid a competitive banking environment.

Company-level read

Ticker impact

$HWBKBullishHigh confidence
Context

Primary focus due to significant earnings growth and bullish sentiment.

Expected impact

Moderate upward movement expected in the near term, with potential for continued growth if earnings momentum persists.

Evidence & confidence

Strong earnings growth, solid capital position, and positive market sentiment support bullish outlook. Slight declines in loans/deposits are offset by overall profitability and capital adequacy.

Market effects

Positive impact on regional banking sector; potential peer stock appreciation.

Likely to bolster regional financial markets due to strong earnings.

Limited, as the news pertains to a regional bank with no immediate global implications.

Counterpoint

The decline in loans and deposits could signal upcoming challenges, and the stock may be overextended in the short term.

Key entities

  • Hawthorn Bancshares, Inc.

    Regional bank reporting strong Q1 earnings.

Related articles

$HWBKMed

HAWTHORN BANCSHARES, INC. (HWBK): Completion of Acquisition or Disposition of Assets

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 PRESS RELEASE – FOR IMMEDIATE RELEASE Hawthorn Bancshares, Inc. Completes Merger with FSC Bancshares, Inc. JEFFERSON CITY, Mo., Sept. 4, 2026 /GLOBE NEWSWIRE/ -- Hawthorn Bancshares, Inc. (“Hawthorn”) (NASDAQ: HWBK), the Missouri-based holding company of Hawthorn Ban

$HWBKMed

Hawthorn Bancshares Reports Second Quarter 2026 Results

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hawthorn Bancshares Reports Second Quarter 2026 Results Jefferson City, MO — July 29, 2026 — Hawthorn Bancshares, Inc. (NASDAQ: HWBK) , (the “Company”), the bank holding company for Hawthorn Bank, reported second quarter 2026 net income of $7.3 million, or earnings p

$SHOPMed

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

Oppenheimer notes improved interest in web and e-commerce software ahead of Q3 results, but AI concerns remain. Shopify (SHOP) is expected to exceed revenue forecasts with strong consumer demand. Wix.com (WIX) may see slower growth due to AI shifts. GoDaddy (GDDY) is on track with forecasts, and Commerce.com (CMCM) expects revenue in line with estimates. Oppenheimer raised Shopify's price target to $205.

$RAPPMedAI 9/10

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.